Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect

被引:569
作者
Kurth, T
Walker, AM
Glynn, RJ
Chan, KA
Gaziano, JM
Berger, K
Robins, JM
机构
[1] Harvard Univ, Brigham & Womens Hosp, Div Aging, Sch Med,Dept Med, Boston, MA 02120 USA
[2] Harvard Univ, Brigham & Womens Hosp, Div Prevent Med, Sch Med,Dept Med, Boston, MA 02120 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[4] i3 Drug Safety, Auburndale, MA USA
[5] Harvard Univ, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Sch Med,Dept Med, Boston, MA 02120 USA
[6] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[7] Boston VA Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA
[8] Univ Munster, Inst Epidemiol & Social Med, D-4400 Munster, Germany
关键词
causality; cerebrovascular accident; confounding factors (epidemiology); data interpretation; statistical; logistic models; models; observational study;
D O I
10.1093/aje/kwj047
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Observational studies often provide the only available information about treatment effects. Control of confounding, however, remains challenging. The authors compared five methods for evaluating the effect of tissue plasminogen activator on death among 6,269 ischemic stroke patients registered in a German stroke registry: multivariable logistic regression, propensity score-matched analysis, regression adjustment with the propensity score, and two propensity score-based weighted methods-one estimating the treatment effect in the entire study population (inverse-probability-of-treatment weights), another in the treated population (standardized-mortality-ratio weights). Between 2000 and 2001, 212 patients received tissue plasminogen activator. The crude odds ratio between tissue plasminogen activator and death was 3.35 (95% confidence interval: 2.28, 4.91). The adjusted odds ratio depended strongly on the adjustment method, ranging from 1.11 (95% confidence interval: 0.67, 1.84) for the standardized-mortality-ratio weighted to 10.77 (95% confidence interval: 2.47, 47.04) for the inverse-probability-of-treatment-weighted analysis. For treated patients with a low propensity score, risks of dying were high. Exclusion of patients with a propensity score of <5% yielded comparable odds ratios of approximately 1 for all methods. High levels of nonuniform treatment effect render summary estimates very sensitive to the weighting system explicit or implicit in an adjustment technique. Researchers need to be clear about the population for which an overall treatment estimate is most suitable.
引用
收藏
页码:262 / 270
页数:9
相关论文
共 39 条
  • [1] Interrater reliability of stroke scales:: The German versions of NIHSS, ESS and Rankin Scale
    Berger, K
    Weltermann, B
    Kolominsky-Rabas, P
    Meves, S
    Heuschmann, P
    Böhner, J
    Neundörfer, B
    Hense, HW
    Büttner, T
    [J]. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 1999, 67 (02) : 81 - 86
  • [2] BERGER K, 2003, NEUROLOGY S, V5, pA429
  • [3] Rare outcomes, common treatments: Analytic strategies using propensity scores
    Braitman, LE
    Rosenbaum, PR
    [J]. ANNALS OF INTERNAL MEDICINE, 2002, 137 (08) : 693 - 695
  • [4] Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders
    Cepeda, MS
    Boston, R
    Farrar, JT
    Strom, BL
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 158 (03) : 280 - 287
  • [5] Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial
    Clark, WM
    Wissman, S
    Albers, GW
    Jhamandas, JH
    Madden, KP
    Hamilton, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2019 - 2026
  • [6] D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
  • [7] 2-B
  • [8] Greenland S, 2000, AM J EPIDEMIOL, V151, P531
  • [9] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
    Hacke, W
    Kaste, M
    Fieschi, C
    von Kummer, R
    Davalos, A
    Meier, D
    Larrue, V
    Bluhmki, E
    Davis, S
    Donnan, G
    Schneider, D
    Diez-Tejedor, E
    Trouillas, P
    [J]. LANCET, 1998, 352 (9136) : 1245 - 1251
  • [10] HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017